Efectiveness of venlafaxine extended release and conventional antidepressants in elderly patients with depressive disorder;Efectividad de la venlafaxina retard y los antidepresivos convencionales en pacientes ancianos con trastorno depresivo

Actas Espanolas de Psiquiatria

Volumn 34, Issue 3, 2006, Pages 153-161

  Agüera Ortiz, Luis ^a   Ramos Garcia I ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Depression; Elderly; Remission; SSRI; Venlafaxine extended release

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; CYCLOHEXANOL DERIVATIVE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DEPRESSION; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTIDEPRESSIVE AGENTS; CITALOPRAM; CYCLOHEXANOLS; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; MIDDLE AGED; PAROXETINE; SEROTONIN UPTAKE INHIBITORS; SERTRALINE;

EID: 33745137139     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Agüera Ortiz L, Martin Carrasco M, Cervilla Ballesteros J. Psiquiatría Geriâtrica. Cap: T. depresivos. Barcelona: Masson, 2002; p. 333-359.
2. a ed. Barcelona: Wavwely Hispánica, 2004; p. 1323-4.
3. Mulsant BM, Gaanguli M. Epidemiology and diagnosis of depression in late life. J Clin Psychiatry 1999;60:9-15.
4. Bruce M, Seeman T, Merrill SS, Blazer DG. The impact of depressive symptomatology on physical disability: MacArthur Studies of Successful Aging. Am J Public Health 1994;84:1796-9.
5. Ganguli M, Dodge HH, Mulsant BH. Rates and predictors of mortality in and aging, rural, community-based cohort: the role of depression. Arch Gen Psychiatry 2002;59:1046-52.
6. Bruce ML. Depresión e incapacidad a edades avanzadas. Am J Geriatr Psychiatry 2001;2:290-301.
7. Szanto K, Gildengers A, Mulsant BH, Brown G, Alexopoulos GS, Reynolds CF 3rd. Identification of suicidal ideation and prevention of suicidal behaviour in the elderly. Drugs Aging 2002;19:11-24.
8. Agüera-Ortiz L, González Parra S, Sánchez Piedra R, Palomo T. Patrones de uso de los antiguos y nuevos antidepresivos en pacientes geriátricos con depresión. Actas Esp Psiquiatr 2000;28: 343-52.
9. Wilson K, Mottram P, Sivanranthan A, Nightingale A. Antidepressant versus placebo for the depressed elderly. From The Cochrane Library; Issue 3, 2004. Chichester (ISSN: 1464-780X).
10. Ray WA, Griffin MR, Schaffner W. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987;316:363-9.
11. Agüera-Ortiz L. Demencia y depresión. Una interrelación multifactorial. En: Palomo T, Beninger RJ, Jiménez-Arriero MA, Archer T, editores. Trastornos cognitivos. Avances neurocientíficos y realidad clínica. Madrid: CYM, 2001; 197-206.
12. Agüera Ortiz L. Demencia. Una aproximación práctica. Madrid: Masson, 1998.
13. Green TD, Reynolds III CF, Mulsant BH, Pollock BG, Miller MD, Houck PR, et al. Accelerating antidepressant response in geriatric depression: a post hoc comparison of combined sleep deprivation and paroxetine versus monotherapy with paroxetine, nortriptylineor placebo. J Geriatr Psychiatry Neurol 1999;12:67-71.
14. Deakin B, Dursun S. Optimizing antidepressant treatment: efficacy and tolerability. Int Clin Pychopharmacol 2002;17:S13-24.
15. Agüera-Ortiz L. Depresión geriátrica. Monografías de Psiquiatría. Madrid: Aula Médica, 2002; p. 1-3.
16. Stage KB, Bech P, Kragh-Sorensen P. Aged-related adverse drug reactions to clomipramine. Acta Psychiatr Scandinava 2002; 105:55-9.
17. Stahl SM. Are two antidepressant mechanisms better than one? J Clin Psychiatry 1997;58:339-40.
18. Thase ME. Effectiveness of antidepressants: Comparative remission rates. J Clin Psychiatry 2003;64:3-7.
19. Montgomery SA, Asberg MA. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9.
20. Hamilton M. The assessment of anxiety status by rating. Br J Med Psychology 1959;32:50-5.
21. Bech P. Rating scales for psychopathology, Health status, and quality of life. Berlin: Springer-Verlag, 1993; p. 333-5.
22. Baldwin RC. The prognosis of depression in later life. En: Holmes C, Howard R, editores. Advances in old age psychiatry. London: Wrightson, 1997; p. 194-226.
23. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-41.
24. Rudolph RL. Achieving remission from depression with venlafaxine and venlafaxine extended release: a literature review of comparative studies with selective serotonin reuptake inhibitors. Acta Psychiatr Scand 2002(Suppl. 415):24-30.
25. th in Boca Raton, Florida.
26. Smeraldi E, Rizzo F, Crespi G. Double-blind, randomized study of venlafaxine, clomipramine and trazodone in geriatric patients with major depression. Prim Care Psychiatry 1998;4:189-95.
27. Mahapatra SN, Hackett D. A randomised, double-blind, parallel-group comparison of venlafaxine and dothiepin in geriatric patients with major depression. Int J Clin Practice 1997;51:209-13.
28. th in Brussels, Belgium.
29. Allard P, Gram L, Timdahl K, Behnke K, Hanson M, Sogarard J. Efficacy and tolerability of venlafaxine in geriatric patients with major depression: a double-blind, randomised 6 month comparative trial with citalopram. Int J Geriatry Psychiatry 2004;19:1123-30.
30. Gastó C, Navarro V, Marcos T, Portella MJ, Torrá M, Rodamilans M. Single blind comparison of venlafaxine and nortryptiline in elderly major depression. J Clin Psychopharmacol 2003;23:21-6.
31. Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3,744 depressed patients. J Clin Psychiatry 1998;59:502-8.